Surrozen (SRZN) Income towards Parent Company (2020 - 2026)
Surrozen (SRZN) posted quarterly Income towards Parent Company of -$32.5 million for Q1 2026, down 126.42% year-over-year from $123.0 million in Q1 2025, and down 259.1% quarter-over-quarter from -$9.1 million in Q4 2025.
Analysis
Surrozen (SRZN) Income towards Parent Company (2020 - 2026) Analysis & Trends
Surrozen's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$32.5 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 126.42% year-over-year to -$32.5 million; the TTM figure through Mar 2026 stood at -$76.6 million (up 10.05% YoY), while the FY2025 annual figure was -$51.9 million, up 31.43% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$32.5 million, down from -$9.1 million in the prior quarter.
- The five-year high for Income towards Parent Company was $104000.0 in Q3 2024, with the low at -$60.1 million in Q4 2024.
- The 5-year median for Income towards Parent Company is -$14.7 million (2023), against an average of -$17.5 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company surged 100.71% in 2024, then plunged 17616.35% in 2025.
- Surrozen's Income towards Parent Company stood at -$1.7 million in 2022, then plunged by 443.05% to -$9.2 million in 2023, then tumbled by 551.78% to -$60.1 million in 2024, then surged by 84.94% to -$9.1 million in 2025, then plunged by 259.1% to -$32.5 million in 2026.
- Business Quant data shows SRZN's Income towards Parent Company at -$32.5 million in Q1 2026, -$9.1 million in Q4 2025, and -$18.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Surrozen | 259.50 Mn | 259.50 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.43 Mn |
| Mar 31, 2026 | -9.54 Mn |
| Dec 31, 2025 | -11.85 Mn |
| Sep 30, 2025 | -9.97 Mn |
| Jun 30, 2025 | -7.99 Mn |
| Mar 31, 2025 | -9.26 Mn |
| Dec 31, 2024 | -8.21 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | -8.56 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -9.22 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -9.65 Mn |
| Mar 31, 2023 | -14.05 Mn |
| Dec 31, 2022 | -1.70 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -14.01 Mn |
| Mar 31, 2022 | -14.44 Mn |
| Dec 31, 2021 | -14.95 Mn |
| Sep 30, 2021 | -13.69 Mn |